FMP

FMP

Enter

CKPT - Checkpoint Therapeut...

Financial Summary of Checkpoint Therapeutics, Inc.(CKPT), Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses o

photo-url-https://financialmodelingprep.com/image-stock/CKPT.png

Checkpoint Therapeutics, Inc.

CKPT

NASDAQ

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

2.12 USD

0.07 (3.3%)

About

ceo

Mr. James F. Oliviero III, C.F.A.

sector

Healthcare

industry

Biotechnology

website

https://www.checkpointtx.com

exchange

NASDAQ

Description

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a tre...

CIK

0001651407

ISIN

US1628282063

CUSIP

162828107

Address

95 Sawyer Road

Phone

781 652 4500

Country

US

Employee

23

IPO Date

Dec 19, 2016

Summary

CIK

0001651407

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

162828107

ISIN

US1628282063

Country

US

Price

2.12

Beta

1.13

Volume Avg.

368.46k

Market Cap

76.64M

Shares

-

52-Week

1.3-3.62

DCF

0.26

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.81

P/B

-

Website

https://www.checkpointtx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CKPT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep